ICON Public Limited Company (ICLR)
| Market Cap | 13.03B +1.3% |
| Revenue (ttm) | 8.29B +3.3% |
| Net Income | 27.04M -96.4% |
| EPS | 0.35 -96.2% |
| Shares Out | 77.15M |
| PE Ratio | 481.96 |
| Forward PE | 15.20 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,325,066 |
| Open | 171.51 |
| Previous Close | 169.31 |
| Day's Range | 167.80 - 173.40 |
| 52-Week Range | 66.57 - 203.91 |
| Beta | 1.20 |
| Analysts | Buy |
| Price Target | 185.56 (+9.84%) |
| Earnings Date | Oct 21, 2026 |
About ICLR
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access ... [Read more]
Financial Performance
In 2025, ICLR's revenue was $8.25 billion, an increase of 0.76% compared to the previous year's $8.19 billion. Earnings were $214.04 million, a decrease of -70.56%.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for ICLR stock is "Buy." The 12-month stock price target is $185.56, which is an increase of 9.84% from the latest price.
News
ICON Announces Private Offering of Notes
DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR) (“ICON”), a world-leading clinical research organization, announced today that its wholly-owned subsidiary, ICON Investments Six Designated Activity Co...
ICON Announces Results of Annual General Meeting
DUBLIN--(BUSINESS WIRE)--ICON Announces Results of Annual General Meeting.
ICON Public Limited Company Earnings Call Transcript: Q2 2026
Q2 2026 saw strong bookings, solid revenue growth, and disciplined cost control, with elevated pass-through activity impacting margins. Strategic investments in AI and Asia-Pacific expansion support long-term growth, while full-year guidance is reaffirmed amid a constructive demand environment.
ICON Public Limited Company Earnings release: Q2 2026
ICON Public Limited Company released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
ICON Public Limited Company Slides: Q2 2026
ICON Public Limited Company has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
ICON Reports Second Quarter 2026 Results
DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a world-leading clinical research organization, today reported its financial results for the second quarter ended June 30, 2026.
ICON announces multi-year collaboration with Anthropic to bring frontier AI to clinical trials
DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR) today announced a multi-year collaboration with Anthropic to bring Claude's AI capabilities across the clinical trial lifecycle. The collaboration furt...
ICON Schedules Second Quarter 2026 Earnings Conference Call
DUBLIN--(BUSINESS WIRE)--ICON Schedules Second Quarter 2026 Earnings Conference Call.
ICON Public Limited Company Earnings Call Transcript: Q1 2026
Q1 2026 results were in line with expectations, with revenue up 0.9% year-over-year and strong commercial momentum reflected in a 1.42x book-to-bill. Guidance for 2026 remains unchanged, with sequential margin improvement expected as business mix shifts toward higher-margin services.
ICON Public Limited Company Earnings release: Q1 2026
ICON Public Limited Company released its Q1 2026 earnings on June 24, 2026, summarizing the period's financial results.
ICON Public Limited Company Slides: Q1 2026
ICON Public Limited Company has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on June 24, 2026.
ICON selects Microsoft as a preferred technology partner to power AI-enabled clinical development
DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR) today announced that it has selected Microsoft as a preferred technology partner – further advancing ICON's previously announced plan to invest in digi...
ICON Schedules First Quarter 2026 Earnings Conference Call
DUBLIN--(BUSINESS WIRE)--ICON Schedules First Quarter 2026 Earnings Conference Call.
ICON Public Limited Company Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 saw improved commercial performance, but results were impacted by an accounting investigation that led to revenue restatements and a $3.9B backlog adjustment. 2026 guidance anticipates modest revenue decline, margin improvement, and continued investment in automation, AI, and high-growth segments.
ICON Public Limited Company Annual report: Q4 2025
ICON Public Limited Company has published its Q4 2025 annual report on May 28, 2026.
ICON Public Limited Company Earnings release: Q4 2025
ICON Public Limited Company released its Q4 2025 earnings on May 28, 2026, summarizing the period's financial results.
ICON Public Limited Company Slides: Q4 2025
ICON Public Limited Company has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on May 28, 2026.
ICON Public Limited Company Annual report: Q4 2025
ICON Public Limited Company has published its Q4 2025 annual report on May 28, 2026.
ICON Reports Fourth Quarter and Full Year 2025 Results and Provides Outcome of Audit Committee Investigation
DUBLIN--(BUSINESS WIRE)--ICON Reports Fourth Quarter and Full Year 2025 Results and Provides Outcome of Audit Committee Investigation.
ICON Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call and Acknowledges Receipt of Deficiency Notice from Nasdaq
DUBLIN--(BUSINESS WIRE)--ICON Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call and Acknowledges Receipt of Deficiency Notice from Nasdaq.
ICON expands US early phase research capabilities with new clinic and outpatient centres
DUBLIN & SAN ANTONIO--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced the expansion of its early phase capabilities with the opening of a new,...
HealthVerity to Acquire Symphony Health, Uniting Clinical Data and Commercial Analytics to Accelerate Breakthroughs Across the Healthcare Ecosystem
Philadelphia, PA, May 05, 2026 (GLOBE NEWSWIRE) -- HealthVerity, Inc., the leader in privacy-protected real-world data exchange and patient identity solutions, today announced that it has entered into...
ICON Provides Update on Audit Committee Investigation and Timing of Fourth Quarter and Full Year 2025 Financial Results
DUBLIN--(BUSINESS WIRE)--ICON Provides Update on Audit Committee Investigation and Timing of Fourth Quarter and Full Year 2025 Financial Results.
ICON and Advarra Introduce New ‘Research-Ready,' Connected Site Network Model
DUBLIN & COLUMBIA, Md.--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, and Advarra, the market leader in regulatory reviews and a leading provider of connect...
Lowey Dannenberg, P.C. is Investigating ICON PLC (NASDAQ: ICLR) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating ICON PLC (“ICON” or the “Company”) (NASDAQ:...